Entera Bio shares traded 25% higher after the firm received a foundational patent from the EU patent office for its oral parathyroid hormone using its platform oral protein delivery technology to treat osteoporosis and hypoparathyroidism.
Anthony Orphanos, a value oriented contrarian investor and money manager, invests in a select number of companies, mostly well-known names, but also one small-cap, Bion Environmental Technologies (BNET:OTCQB), that you probably never heard of.
Clearside Biomedical shares reached a new 52-week high after the company reported that the first cohort in its dose-escalating Oasis Trial of CLS-AX for treatment of neovascular age-related macular degeneration met all primary endpoints.
They have Buy recommendations on Bion Environmental Technologies (BNET:OTCQB), which holds the potential to "revolutionize agriculture and water quality," and also has a plan to produce organic grain-fed beef on a large scale.
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus.
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points.